Cerebrovascular Accident Clinical Trial
— RAI PAR BLOCOfficial title:
Biomechanical and Neurophysiological Evaluation of the Effect of a Motor Block and an Injection of Botulinum Toxin on the Stiffness of the Paretic Sural Triceps Muscle
Verified date | July 2023 |
Source | Nantes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The research "Biomechanical and neurophysiological evaluation of the effects of a motor block and an injection of botulinum toxin on the stiffness of the paretic sural triceps muscle" will study the response to passive stretching in the neurological patient presenting spastic paresis after a stroke.
Status | Completed |
Enrollment | 27 |
Est. completion date | July 10, 2023 |
Est. primary completion date | July 10, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria : - Patient with signed consent, - Be over 18 and under 80 years of age, - Have suffered a stroke (medical diagnosis), - Spasticity of the triceps surae with a modified Ashworth score of the triceps sural of at least 1, - Medical indication to perform a treatment of spasticity of the sural triceps by ITB, requiring a prior selective nerve block to qualify or disqualify this procedure (depending on the effectiveness, reaction / sensations / perceptions of the patient), - Cognitive abilities compatible with experimentation: absence of language or judgment impairments that prevent the understanding of the research or the expression of agreement. An aphasia severity score > or equal to 3 will be required for inclusion, - Be eligible for social security. Exclusion Criteria: - Person in an emergency situation, deprived of liberty, or not benefiting from the social protection system, - Person under 18 years of age or under any legal protection measure whatsoever, - Unbalanced epileptic disorder; tension variability, - History of calf surgery (scarring areas that disrupt ultrasound elastography exploration), - Disorders related to bed rest: thromboembolic disorders, bedsores, respiratory or digestive disorders, - Previous botulinum toxin injection injection less than 3 months ago (contraindication to a new botulinum toxin injection), - Contraindication to an injection of botulinum toxin abobotulinum toxin A (Dysport®), - Patient under anti-coagulant, - Aphasia or cognitive impairment interfering with task comprehension, - Contraindication to ankle manipulation: fracture, phlebitis, pressure sore in the areas of support of the orthosis, - Pregnant or breastfeeding women. Translated with www.DeepL.com/Translator (free version) |
Country | Name | City | State |
---|---|---|---|
France | CHU de Nantes | Nantes |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Biomecanical evaluation of the selective nerve block effects on soleus muscle stiffness (distal part) during stretching of the plantar flexor muscles in the patient after a stroke. | Study of the soleus (distal) muscle stiffness before and after the realization of selective nerve block of the soleus nerve. The muscle stiffness is assessed by measuring the shearing module (in kilopascals) by elastography SSI during the slow passive stretching (2°/sec) realized by an isokinetic ergometer during the examination before and after the selective nerve block realization. | 20 minutes post selective nerve block at Day 0 | |
Secondary | Biomechanical effect of selective nerve block on proximal soleus muscle stiffness when stretching plantar flexor muscles | Study of the variation of the proximal soleus muscle stiffness between before and after performing the selective nerve block of the soleus nerve | 20 minutes post selective nerve block at Day 0 | |
Secondary | Neurophysiological effects of the motor block on nerve transmission and muscle activation. | Neurophysiological effects will be evaluated by: (i) the variations in amplitude and latency of the M wave, of the H response, and of the Hmax/Mmax ratio, and (ii) the change in muscle activity (measured by electromyography) between before and after selective nerve block. Muscle activity will be recorded during the entire passive dorsal ankle flexion movement with the dynamometer. It will be quantified by the area under the curve of the EMG signal recorded for each site (distal soleus and proximal soleus), after usual treatment of the EMG signal to obtain an envelope (filtering, rectification and normalization) | 20 minutes post selective nerve block at Day 0 | |
Secondary | Inter-individual variability of the decrease in muscle stiffness after selective nerve block | Variability of the selective nerve block response between the patients, measures of the decrease in muscle stiffness will be taken into account for each musce site : distal soleus and proximal soleus. | 20 minutes post selective nerve block at Day 0 | |
Secondary | Biomechanical effect of botulinum toxin injection on muscle stiffness of the soleus (distal part) when stretching the plantar flexor muscles. | Variation of the muscle stiffness of the distal and proximal soleus between before and after botulinum toxin injection. | Day 28 post botulinum toxin injection | |
Secondary | Inter-individual variability of the decrease in muscle stiffness after botulinum toxin injection. | Inter-patient variability for the answer to the botulinum toxin injection, muscle stiffness reduction measures will be taken into account for each muscle site : distal soleus and proximal soleus. | Day 28 post botulinum toxin injection | |
Secondary | Relationship between selective nerve block effect and botulinum toxin injection effect. | The relationship between the selective nerve block effect and the botulinum toxin injection effect will be evaluated by calculating correlations between the stiffness variation before and after each intervention. | Day 28 post botulinum toxin injection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05477238 -
Oxygen Consumption in Post-stroke Patients During Various Walking Activities Compared to Healthy Controls
|
N/A | |
Completed |
NCT00046293 -
ReoPro and Retavase to Treat Acute Stroke
|
Phase 2 | |
Completed |
NCT04584645 -
A Digital Flu Intervention for People With Cardiovascular Conditions
|
N/A | |
Completed |
NCT01116544 -
Treatment of Chronic Stroke With AMES + EMG Biofeedback
|
N/A | |
Withdrawn |
NCT04991038 -
Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients
|
N/A | |
Active, not recruiting |
NCT02563886 -
Electrically Assisted Movement Therapy
|
N/A | |
Recruiting |
NCT02446730 -
Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
Completed |
NCT02141932 -
Pocket-size Cardiovascular Ultrasound in Stroke
|
N/A | |
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Recruiting |
NCT01769326 -
Influence of Timing on Motor Learning
|
N/A | |
Recruiting |
NCT02557737 -
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities
|
Phase 3 | |
Terminated |
NCT01705353 -
The Role of HMGB-1 in Chronic Stroke
|
N/A | |
Completed |
NCT01423201 -
Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
|
||
Completed |
NCT01656876 -
The Effects of Mirror Therapy on Upper Extremity in Stroke Patients
|
N/A | |
Completed |
NCT01182818 -
Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease
|
N/A | |
Completed |
NCT00542256 -
tDCS and Physical Therapy in Stroke
|
N/A | |
Withdrawn |
NCT00573092 -
Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs
|
N/A | |
Completed |
NCT00377689 -
Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke
|
Phase 2 | |
Recruiting |
NCT00166751 -
Sonographic Assessment of Laryngeal Elevation
|
N/A | |
Terminated |
NCT00120289 -
Niacin Plus Statin to Prevent Vascular Events
|
Phase 3 |